GSK Plans To Wield Aggressive Bolt-On Acquisition Strategy
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline is planning on moving aggressively beyond its core prescription drug business with possible bolt-ons in consumer health among other categories, CEO Andrew Witty told investors at a recent Goldman Sachs conference in New York
You may also be interested in...
GSK Upbeat On Alli In EU As Global Consumer Sales Show Healthy Gains
Alli is off to the races in Europe, where it is generating high sales since launching in April, GlaxoSmithKline says
GSK Upbeat On Alli In EU As Global Consumer Sales Show Healthy Gains
Alli is off to the races in Europe, where it is generating high sales since launching in April, GlaxoSmithKline says
GSK Upbeat On Alli In EU As Global Consumer Sales Show Healthy Gains
Alli is off to the races in Europe, where it is generating high sales since launching in April, GlaxoSmithKline says